Stent coverage and neo-intima hyperplasia
T2D, weight loss, diabetes
PROLIFERATION, DIABETES
In the present study we found no evidence that the GLP-1R agonist exenatide improves coronary stent endothelization in subjects with T2D. Since the same type of stent was implanted in all subjects and that the baseline clinical data and the OCT procedural characteristics were well balanced, we consider the comparison between groups reliable. Despite no significant difference in metformin and insulin doses during the study, glycemic control and weight loss were improved in the exenatide group compared to control group. Although the role of glycemic control in subjects with diabetes and DES endothelization remains elusive, [Procedural baseline characteristics, e.g. good stent expansion and the observed low frequency of significant malapposition by OCT, may have prompted an optimal stent endothelization in both groups as the percentage of covered struts is somehow higher than in previous rapports [GLP-1R activation by exenatide has been demonstrated inducing endothelial proliferation, [